INTRODUCTION

Pilocytic astrocytomas are one of the most common benign brain neoplasms of childhood but remain exceedingly rare in adults accounting for only 0.8% of central nervous system tumors in patients >20 years of age. [30,32] Although adult pilocytic astrocytomas (APAs) are thought to have an excellent prognosis, especially following complete surgical resection, some have suggested that APAs may exhibit higher recurrence rates with increased incidence of malignant transformation than their pediatric counterparts. [6,9,12,19,24,30,37,38,40,41] Given the low incidence of recurrent APAs, no management guidelines exist, however, those presenting...
with local recurrence are typically treated through repeat resection with radiation and chemotherapy reserved for inoperable lesions or as adjuvant therapy for those tumors demonstrating high-grade features.\cite{3,4,21,22,37,39,40,44}

Leptomeningeal dissemination and spontaneous malignant degeneration are uncommon and present significant surgical and oncologic challenges.\cite{8,26}

To that end, we present a rare case of a recurrent APA exhibiting intraventricular and leptomeningeal spread <1 year after near-total resection. We also provide a review of the available literature discussing management of recurrent APAs.

**CLINICAL PRESENTATION**

An otherwise healthy 26-year-old female presented in 2017 with severe headaches, nausea, vomiting, and visual changes. After fundoscopic examination demonstrated Grade 5 papilledema, contrast-enhanced brain magnetic resonance imaging (MRI) was performed revealing a 4.8 × 4.4 × 4.1-cm mass centered in the fourth ventricle resulting in obstructive hydrocephalus [Figure 1]. She subsequently underwent near-total resection with only a small portion of the tumor intentionally left on the floor of the fourth ventricle in an effort to prevent damage to the brainstem. Postoperatively, her hydrocephalus did not resolve and required ventriculoperitoneal shunting. Following this second procedure, she progressed well and was discharged home with no postoperative complications. The final pathology demonstrated presence of eosinophilic granular bodies and Rosenthal fibers with immunohistochemistry showing focal Olig-2 staining as well as GFAP and vimentin positivity confirming that the tumor was a World Health Organization Grade 1 pilocytic astrocytoma [Figure 2]. IDH-1, p53, neurofilament, and BRAF gene rearrangement testing were negative. Despite initial improvement in her symptoms, at 10 months postsurgery, she developed new-onset headaches, confusion, and lethargy. Repeat MRI demonstrated widespread tumor recurrence throughout the entire ventricular system and the subarachnoid spaces of the left cerebellopontine angle (CPA) suggesting leptomeningeal spread [Figure 3]. Due to the unresectable nature of the recurrence, the patient declined any further intervention and succumbed to her disease 6 months later.

**DISCUSSION**

Pilocytic astrocytomas are one of the most common gliomas of childhood. However, in adults, they are much less frequent with an incidence of 3.4/1 million.\cite{32} In children, they usually occur in the cerebellum, whereas in adults, they are equally likely to be supratentorial.\cite{7} Due to their frequently benign nature, these tumors typically only present after they have grown large enough to produce symptoms of increased intracranial pressure or obstructive hydrocephalus.\cite{3,37}

Given the rarity of APAs, most neurosurgeons manage them based on the extrapolation of data from pediatric cases. However, recent studies have suggested that APAs may behave more aggressively with higher rates of recurrence and malignant transformation than their pediatric counterparts.\cite{12,24,37,40}

Yet, no consensus on the management and treatment of recurrent APAs exists. Here, we discuss the current understanding of APA behavior and the possible therapeutic avenues that have been explored thus far.

Several studies have shown that increasing patient age is correlated with lower rates of overall survival in pilocytic astrocytomas with 5-year survival dropping from 96.5% in pediatric patients to approximately 53% in patients older than 60.\cite{7,23}

Furthermore, APAs appear to have increased recurrence rates and higher potential to undergo

---

**Figure 1:** Imaging performed in April 2017. (a) Preoperative T1 contrast enhancing MRI demonstrating a well-circumscribed lesion within the fourth ventricle. (b) Preoperative T2 MRI demonstrating no significant surrounding edema or infiltration of the normal brain parenchyma. (c) Preoperative DWI demonstrating no diffusion restriction. (d) Postoperative T1 contrast enhancing MRI demonstrating no obvious residual tumor.
malignant transformation. Maximal safe resection should be the goal whenever feasible as studies have shown that extent of resection correlates directly with increased survival.\cite{12,37} However, postsurgical management of APAs, including adjuvant treatments for subtotal resections and surveillance imaging to identify tumor progression/recurrence, remains controversial.

In the pediatric population, several retrospective series examined the benefit of surveillance imaging for pilocytic astrocytomas and concluded that patients with a gross total resection have a very low likelihood of recurrence and may not benefit from long-term surveillance.\cite{1,10,27} They found that most recurrences happened within 3 years of resection and thus advocated for more intensive screening during the 1st year followed by incrementally larger observation periods over a total of 3–5 years. However, other series identified recurrences at even later time points and thus argued for more long-term follow-up.\cite{11} If we adapt these findings to APAs, which are known to have higher recurrence rates and less favorable prognoses than their pediatric counterparts, then it may be beneficial to obtain more frequent interval imaging within the first few years after resection and continue to follow these patients long-term, especially in those with known subtotal resections.\cite{6,24}

Little data exist to help guide postsurgical adjuvant therapy for subtotally resected APAs. Radiation therapy (XRT) has been evaluated in several studies with mixed findings. A recent study evaluating overall survival following subtotal resection of APAs found that those patients who received postoperative XRT had significantly higher mortality rates compared to those that received surveillance alone.\cite{20} Other retrospective studies have found good local control in subtotally resected or recurrent APAs that underwent XRT but found no difference overall survival.\cite{14,15,18,23,42,43} Although these studies are susceptible to selection bias, as older patients, and lesions with evidence of increased aggressiveness or eloquent location tend to more frequently receive postoperative XRT, their results emphasize the need for future prospective studies evaluating the role of XRT in APAs.\cite{16,24,37,40}

Although no standard chemotherapeutic regimen exists for APAs, various drug combinations, with or without XRT, have been used in recurrent/inoperable pilocytic astrocytomas with varying degrees of effectiveness.\cite{2,5,17,29,39} Since pilocytic astrocytomas are known to

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure2.png}
\caption{Figure 2: (a) Low-power view demonstrating typical oval nuclei, low mitotic activity, and Rosenthal fibers. (b) High-power view demonstrating eosinophilic granular bodies.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure3.png}
\caption{Figure 3: Imaging performed in March 2018. (a) T1 contrast-enhanced MRI demonstrating tumor recurrence within the frontal horns of the lateral ventricle. (b) T1 MRI demonstrating recurrent tumor within the third ventricle. (c) T1 MRI demonstrating leptomeningeal enhancement in the left cerebellopontine angle and temporal horns.}
\end{figure}
express higher levels of VEGF-A, immunotherapy agents such as bevacizumab have also been utilized in inoperable cases and have demonstrated promising results in the adult population. Unfortunately, BRAF V600E mutations are very rare in APAs, thus limiting the use of inhibitors such as dabrafenib. However, upregulated mTOR signaling appears to be present in a majority of cases providing another potential avenue for therapeutic targeting.

Leptomeningeal disease in recurrent APAs remains significantly difficult to manage because, by definition, it is unresectable. Biopsy may be warranted to determine if the lesion has malignantly transformed. In addition, molecular testing may also increase diagnostic and prognostic accuracy as DNA methylation has been shown to help determine tumor grade when histologic features alone remain ambiguous. Although it is still unclear what factors influence the development of leptomeningeal spread, it has been suggested that subtotal resections of periventricular APAs may increase the risk of recurrence in the leptomeninges.

In our patient, the tumor involved the fourth ventricle and resection may have led to leptomeningeal spread within the CPA. However, this does not fully explain how the tumor casted the entire ventricular system. Given that the patient was shunted for hydrocephalus, this may have led to ventricular seeding yet this would likely have tracked along the catheter rather than involving even the contralateral lateral ventricle. Furthermore, even in those patients who develop leptomeningeal recurrence, casting of all the ventricles has never been reported. This suggests the presence of a much more insidious process. Unfortunately, in our patient, the recurrence was inoperable, and the lesions were too diffuse to perform stereotactic radiosurgery so whole-brain XRT and chemotherapy were her only options. As a result, the patient declined a biopsy to evaluate for malignant transformation and did not pursue any further treatment.

CONCLUSION
We report a rare case of a recurrent APA presenting with diffuse intraventricular and leptomeningeal spread. This atypical and fatal case highlights the need for improved management guidelines and better diagnostic criteria for these tumors in the adult population. Novel molecular profiling may help detect subtle differences in tumor grade and, in turn, better direct adjuvant therapy in patients with known residual or recurrent disease. Although thought to be a benign neoplasm, close interval follow-up with serial imaging may be useful in those patients with known residual tumor.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Alford R, Gargan L, Bowers DC, Klesse LJ, Weprin B, Koral K. Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma. J Neurooncol 2016;130:149-54.
2. Bian SX, McAleer MF, Vats TS, Mathajan A, Grosshans DR. Pilocytic astrocytoma with leptomeningeal dissemination. Childs Nerv Syst 2013;29:441-50.
3. Bond KM, Hughes JD, Porter AL, Orina J, Fang S, Parney IF. Adult pilocytic astrocytoma: An institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg 2018;110:276-83.
4. Bowers DC, Krause TP, Aronson LJ, Barzi A, Burger PC, Carson BS, et al. Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg 2001;34:229-34.
5. Brown MT, Friedman HS, Oakes WJ, Boyko OB, Hockenberger B, Schold SC Jr. Chemotherapy for pilocytic astrocytomas. Cancer 1993;71:3165-72.
6. Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, et al. Adult patients with supratentorial pilocytic astrocytomas: A prospective multicenter clinical trial. Int J Radiat Oncol Biol Phys 2004;58:1153-60.
7. Burkhard C, Di Patre PL, Schuler D, Schuler G, Yasargil MG, Yonekawa Y, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 2003;98:1170-4.
8. Coelho J, Nunes S, Saígdo D. Spontaneous malignant transformation of a pilocytic astrocytoma of cerebellum: Case report. Child Neurol Open 2015;2:1-5.
9. Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: Pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:775-88.
10. Dodghshun AJ, Maixner WJ, Hansford JR, Sullivan MJ. Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: Justification for reducing surveillance imaging. J Neurosurg Pediatr 2016;17:569-72.
11. Dorward IG, Luo J, Perry A, Gutmann DH, Mansur DB, Rubin JB, et al. Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr 2010;6:346-52.
12. Ellis JA, Waziri A, Balmaceda C, Canoll P, Bruce JN, Sisti MB. Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol 2009;95:377-82.
13. Green R, Woyshner E, Quan J, Pope W, Cloughesy T. Treatment
of unresectable adult pilocytic astrocytoma with bevacizumab with or without temozolomide (P01.097). Neurology 2013;80 Suppl 7:P01.097.

14. Hallemeier CL, Pollock BE, Schomberg PJ, Link MJ, Brown PD, Stafford SL. Stereotactic radiosurgery for recurrent or unresectable pilocytic astrocytoma. Int J Radiat Oncol Biol Phys 2012;83:107-12.

15. Ishkanian A, Laperriere NJ, Xu W, Millar BA, Payne D, Mason W, et al. Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer 2011;117:4070-9.

16. Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: Analysis of the surveillance, epidemiology, and end results program of the national cancer institute. J Neurooncol 2012;108:187-93.

17. Kageji T, Nagahiro S, Horiguchi H, Watanabe T, Suzuya H, Okamoto Y, et al. Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optic- hypothalamic juvenile pilocytic astrocytoma in an infant: A case report. J Neurooncol 2003;62:281-7.

18. Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for pilocytic astrocytomas part 1: Outcomes in adult patients. J Neurooncol 2009;95:211-8.

19. Kayama T, Tominaga T, Yoshimoto T. Management of pilocytic astrocytoma. Neurosurg Rev 1996;19:217-20.

20. Khalfallah AM, Jimenez AE, Shah PP, Brem H, Mukherjee D. Effect of radiation therapy on overall survival following subtotal resection of adult pilocytic astrocytoma. J Clin Neurosci 2020;81:634-5.

21. Krieger MD, Gonzalez-Gomez I, Levy ML, McComb JG. Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas. Pediatr Neurosurg 1997;27:1-11.

22. Lee KJ, Marchan E, Peterson J, Harrell AC, Quinones-Hinojosa A, Brown PD, et al. Management and survival of adult patients with pilocytic astrocytoma in the national cancer database. World Neurosurg 2018;112:e881-7.

23. Lizzarraga KJ, Gorgulho A, Lee SP, Rauscher G, Selch MT, DeSalles AA. Stereotactic radiation therapy for progressive residual pilocytic astrocytomas. J Neurooncol 2012;109:129-35.

24. Mair MJ, Wohrer A, Furtner J, Simonovska A, Kiesel B, Oberndorfer S, et al. Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. J Neurooncol 2012;109:129-35.

25. MamelaK AN, Prados MD, Obana WG, Cogen PH, Edwards MS. Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg 1994;81:24-30.

26. Mazloom A, Hodges JC, Teh BS, Chintagumpala M, Paulino AC. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int J Radiat Oncol Biol Phys 2012;84:350-4.

27. McAuley E, Brophy H, Hayden J, Pettorini B, Parks C, Avula S, et al. The benefit of surveillance imaging for pediatric cerebellar pilocytic astrocytoma. Childs Nerv Syst 2019;35:801-5.

28. Narayan A, Jallo G, Huisman TA. Extracranial, peritoneal seeding of primary malignant brain tumors through ventriculo-peritoneal shunts in children: Case report and review of the literature. Neuroradiol J 2015;28:536-9.

29. Nishio S, Morioka T, Takeshita I, Shono T, Inamura T, Fujiiwara S, et al. Chemotherapy for progressive pilocytic astrocytomas in the chiasmato-hypothalamic regions. Clin Neurol Neurosurg 1995;97:300-6.

30. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendrogial gliomas. J Neuropath Exp Neurol 2005;64:479-89.

31. Ono T, Takahashi M, Hatakeyama J, Oda M, Sahm F, Nano H, et al. Clinical significance of molecular diagnosis of pilocytic astrocytoma: A case report. NMC Case Rep J 2019;6:95-9.

32. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 2014;16 Suppl 4:v1-63.

33. Pathak P, Kumar A, Jha P, Purkait S, Faruq M, Suri A, et al. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. Brain Pathol 2017;27:580-9.

34. Roelz R, Reinacher P, Jabbbarli R, Kraeutle R, Hippchen B, Egger K, et al. Surgical ventricular entry is a key risk factor for leptomeningeal metastasis of high grade gliomas. Sci Rep 2015;5:17758.

35. Sie M, de Bont ES, Scherpen EJ, Hoving EW, den Dunnen WF. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma: is it much different from glioblastoma? Neuropathol Appl Neurobiol 2010;36:636-47.

36. Soliman RK, Budai C, Mundada P, Aljohani B, Rushing EJ, Kollias SS. Suprasellar pilocytic astrocytoma in an adult with hemorrhage and leptomeningeal dissemination: Case report and review of literature. Radiol Case Rep 2016;11:411-8.

37. Stuer C, Vilz B, Majores M, Becker A, Schramm J, Simon M. Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer 2007;110:2799-808.

38. Tabash MA. Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. J Neurol Sci 2019;400:148-52.

39. Tamura M, Zama A, Kurihara H, Fujimaki H, Imai H, Kano T, et al. Management of recurrent pilocytic astrocytoma with leptomeningeal dissemination in childhood. Childs Nerv Syst 1998;14:617-22.

40. Theeler BJ, Ellezam B, Sadighi ZS, Mehta V, Tran MD, Adesina AM, et al. Adult pilocytic astrocytomas: Clinical features and molecular analysis. Neuro Oncol 2014;16:841-7.

41. Tibbetts KM, Emmett RJ, Gao F, Perry A, Gutmann DH, Leonard JR. Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol 2009;117:657-65.

42. Trifiletti DM, Peach MS, Xu Z, Kersh R, Showalter TN, Sheehan JP. Evaluation of outcomes after stereotactic radiosurgery for pilocytic astrocytoma. J Neurooncol 2017;134:297-302.
43. Trunin I, Golanov AV, Konovalov AN, Shishkina LV, Gorlachev GE, Gorelyshev SK, et al. Stereotactic radiotherapy and radiosurgery in treatment of patients with deep-seated pilocytic astrocytomas. Zh Vopr Neirokhir Im N N Burdenko 2012;76:64-78; discussion 78.

44. Wasilewski A, Mohile N. Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. CNS Oncol 2018;7:CNS26.

**How to cite this article:** Khan K, Luther E, Morrell AA, Tan SK, Eichberg DG, Shah AH, et al. Recurrent adult pilocytic astrocytoma presenting with intraventricular and leptomeningeal spread. Surg Neurol Int 2021;12:359.